Skin Diseases  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Skin Diseases
EPHOS-B, NCT01104571 / 2008-005466-30: Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

Checkmark P3 trial design
Dec 2011 - Dec 2011: P3 trial design
Active, not recruiting
3
257
Europe
trastuzumab, lapatinib ditosylate, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Institute of Cancer Research, United Kingdom, University of Manchester, Manchester University NHS Foundation Trust, Cancer Research UK, Novartis
Breast Cancer
08/17
09/25

Download Options